Pharmacology News and Research

Latest Pharmacology News and Research

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Institute for Molecular Medicine Finland will launch a cell microarray screening research program utilizing the Aushon 2470 Arrayer technology.

26 Mar 2010

Payers can improve risk-sharing approaches for expensive therapies and technology

Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, announced today that it has published the collective recommendations of an international team of healthcare experts on how payers can improve their risk-sharing approaches for expensive new therapies and technology.

25 Mar 2010

Study: MetAP inhibitors prevent TB growth in test tubes

Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria's survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein's activity and, in a test tube, blocks TB growth, demonstrating that the protein is indeed a vulnerable target.

25 Mar 2010

Protein deficiency in Down syndrome patients could contribute to cognitive impairment and congenital heart defects

Conventional wisdom among scientists for years has suggested that because individuals with Down syndrome have an extra chromosome, the disorder most likely results from the presence of too many genes or proteins contained in that additional structure.

24 Mar 2010

Aureus Pharma to participate in € 118 million BioIntelligence R&D programme

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today it’s participation in a EUR118.2 million (USD 160 million) project. The project is the Biointelligence R&D programme designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases to improve research efficiency.

23 Mar 2010

Researchers investigate link between consumption of high-fructose corn syrup and obesity

A Princeton University research team has demonstrated that all sweeteners are not equal when it comes to weight gain: Rats with access to high-fructose corn syrup gained significantly more weight than those with access to table sugar, even when their overall caloric intake was the same.

23 Mar 2010

Sir James Black inventor of beta-blockers passes away

Sir James Black passed away on Monday after a long illness, he was 85. Sir James Black is credited as the inventor of the beta-blocker drugs in 1962. These are drugs which play an important role in the treatment of angina and heart attacks. They are regarded as one of the major medical breakthroughs of the 20th Century in Pharmacology. Born in Uddingston, Lanarkshire, Sir James Black studied medicine at St. Andrews University.

23 Mar 2010

AccessPhysiotherapy online resource launched for PT students and educators

AccessPhysiotherapy™, an essential online resource for physical therapy students and educators integrating renowned medical resources with rich multimedia and customizable curriculum functionality, is the latest product to be launched in McGraw-Hill Professional's acclaimed suite of digital learning platforms for medical students and physicians.

23 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or carcinogenic byproduct.

18 Mar 2010

SANTE study: Deep brain stimulation can reduce seizures

A recent study organized by Stanford University researchers found patients with refractory partial and secondarily generalized seizures had a reduction in seizures after deep brain stimulation. This multi-center clinical trial determined that the benefits of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE) persisted and by 2 years there was a 56% reduction in seizure frequency.

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.

From Parexel 17 Mar 2010

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Consumers are becoming more price-sensitive toward brand-name drugs

The results of a new Pharma Insight study released today by Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, is not exactly what the doctor ordered. The company's annual analysis of the U.S. pharma market suggests that the economy has led to increased patient participation in decisions about prescription drugs.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial perfusion imaging (MPI) agent. The study of nine patients compared rest-stress flurpiridaz F 18 PET MPI, with rest-stress technetium-99m (Tc-99m) labeled single photon emission computed tomography (SPECT) for the detection and evaluation of coronary artery disease (CAD).

16 Mar 2010

Pharmacology News and Research

Latest Pharmacology News and Research

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Payers can improve risk-sharing approaches for expensive therapies and technology

Study: MetAP inhibitors prevent TB growth in test tubes

Protein deficiency in Down syndrome patients could contribute to cognitive impairment and congenital heart defects

Aureus Pharma to participate in € 118 million BioIntelligence R&D programme

Researchers investigate link between consumption of high-fructose corn syrup and obesity

Sir James Black inventor of beta-blockers passes away

AccessPhysiotherapy online resource launched for PT students and educators

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

NexACT technology demonstrates ability to deliver Taxol subcutaneously

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

SANTE study: Deep brain stimulation can reduce seizures

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

Consumers are becoming more price-sensitive toward brand-name drugs

Key cellular defect in protein synthesis can lead to cancer susceptibility

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Pharmacology News and Research

Latest Pharmacology News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in